Page last updated: 2024-11-05

acadesine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Acadesine (also known as AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide) is a synthetic compound that activates AMP-activated protein kinase (AMPK). AMPK is a key regulator of cellular energy metabolism, playing a role in glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. Acadesine is studied for its potential therapeutic benefits in a range of conditions, including diabetes, obesity, cardiovascular disease, and neurodegenerative disorders. It is believed to improve insulin sensitivity, reduce inflammation, and protect against oxidative stress. Acadesine has been investigated in clinical trials, but its therapeutic efficacy remains under investigation. Acadesine can be synthesized by several methods, including enzymatic reactions and chemical synthesis.'

Cross-References

ID SourceID
PubMed CID17513
CHEMBL ID1551724
CHEBI ID28498
SCHEMBL ID219336
MeSH IDM0058131

Synonyms (102)

Synonym
SRI-4077-02
arasine
5-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]imidazole-4-carboxamide
5-amino-1-.beta.-d-ribofuranosyl-1h-imidazole-4-carboxamide
protara
aicar, >=98% (hplc), powder
gp-1-110
acadesine (usan/inn)
D02742
HSCI1_000213
nsc-105823
5-amino-4-imidazolecarboxamide ribofuranoside
1h-imidazole-4-carboxamide, 5-amino-1-.beta.-d-ribofuranosyl-
5-aminoimidazole-4-carboxamide ribonucleoside
nsc105823
aic-riboside
2627-69-2
aica-riboside
5-aminoimidazole-4-carboxamide riboside
C04663 ,
5-amino-1-beta-d-ribofuranosylimidazole-4-carboxamide
5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside
aica riboside
acadesine ,
NCGC00165736-01
5-aminoimidazole-4-carboxamide-1-beta-riboside
NCGC00096051-02
5-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-imidazole-4-carboxamide
CHEMBL1551724
chebi:28498 ,
NCGC00165736-03
5-amino-1-beta-d-ribofuranosyl-4-imidazolecarboxamide
einecs 220-097-5
acadesina
gp 1-110
53ief47846 ,
5-amino-1beta-d-ribofuranosylimidazole-4-carboxyamide
acadesine [usan:inn:ban]
1h-imidazole-4-carboxamide, 5-amino-1-beta-d-ribofuranosyl-
unii-53ief47846
imidazole-4-carboxamide, 5-amino-1-beta-d-ribofuranosyl-
acadesina [inn-spanish]
acadesinum
5-amino-1-beta-ribofuranosyl-imidazole-4-carboxamide
5-amino-1-beta-d-ribofuranosyl-1h-imidazole-4-carboxamide
acadesinum [inn-latin]
tox21_111551
dtxcid3026015
cas-2627-69-2
dtxsid5046015 ,
smr003435998
MLS004774120
ath-001
acadra
gp-1-110-0
sch-900395
c9h14n4o5
AKOS016004462
5-amino-4-imidazolecarboxamide riboside
S1802
acadesine [mart.]
5-aminoimidazole-4-carboxamide-1-.beta.-d-ribofuranoside
acadesine [usan]
5-amino-1-.beta.-d-ribofuranosylimidazole-4-carboxamide
acadesine [mi]
acadesine [inn]
acadesine [who-dd]
5-amino-1-b-d-ribofuranosylimidazole-4-carboxamide
gtpl5133
SCHEMBL219336
DB04944
CS-1951
HY-13417
MLS006010069
tox21_111551_1
NCGC00165736-04
5-amino-1-beta-ribofuranosylimidazole-4-carboxamide
RTRQQBHATOEIAF-UUOKFMHZSA-N
J-700140
n(1)-(beta-d-ribofuranosyl)-5-aminoimidazole-4-carboxamide
5-amino-1-(beta-d-ribofuranosyl)-1h-imidazole-4-carboxamide
ec number 220-097-5
5-amino-1-ribofuranosylimidazole-4-carboxamide
n1-(?-d-ribofuranosyl)-5-aminoimidazole-4-carboxamide
HB2152
n1-(beta-d-ribofuranosyl)-5-aminoimidaz ole-4-carboxamide
5-amino-1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1h-imidazole-4-carboxamide
AC-26840
SRI-4077_04
mfcd00869751
aicar (acadesine)
ath001
Q4671562
EX-A7096
AS-13787
aica-riboside; lc-tdda; ce40
CCG-267038
NCGC00165736-16
nsc-811018
nsc811018
acadesine (aicar)
5-aminoimidazole-4-carboxamide 1-(1/4)?-d-ribofuranoside

Research Excerpts

Overview

Acadesine is an adenosine receptor agonist (ARA) in development for the treatment of ischaemia-reperfusion injury and chronic lymphocytic leukaemia.

ExcerptReferenceRelevance
"Acadesine is a nucleoside analogue with known activity against B-cell malignancies. "( Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.
Campàs, C; Campo, E; Colomer, D; de Frías, M; Lee-Vergés, E; López-Guerra, M; Montraveta, A; Rodríguez, V; Roldán, J; Rosich, L; Roué, G; Xargay-Torrent, S, 2015
)
2.11
"Acadesine is an adenosine-regulating agent that increases bioavailability of adenosine and has important metabolic effects, partly through activation of the key metabolic regulatory enzyme, AMP-activated protein kinase."( Acadesine, an adenosine-regulating agent with the potential for widespread indications.
Drew, BG; Kingwell, BA, 2008
)
3.23
"Acadesine is an adenosine receptor agonist (ARA) in development for the treatment of ischaemia-reperfusion injury and chronic lymphocytic leukaemia. "( Acadesine: AICA riboside, ARA 100, arasine, GP 1 110.
, 2008
)
3.23
"Acadesine is a cardioprotective nucleoside that can attenuate postischemic contractile dysfunction in the isolated heart even if administered at reperfusion, thereby implying an effect on a reperfusion-induced component of injury. "( Acadesine prevents oxidant-induced damage in the isolated guinea pig heart.
Bullough, DA; Fox, MH; Metzner, EK; Mullane, KM; Potter, S; Zhang, C, 1993
)
3.17
"Acadesine is a ribose-substituted imidazole with antithrombotic properties mediated by adenosine. "( Acadesine reduces the frequency of coronary artery reocclusion following rt-PA induced thrombolysis in the dog.
Bullough, D; Henry, C; Mullane, K; Wong, S; Young, MA, 1995
)
3.18

Effects

Acadesine has shown in vitro to selectively induce apoptosis in B cells from chronic lymphocytic leukemia (CLL) patients. It has proven intravenous efficacy in the amelioration of ischaemic reperfusion injury associated with coronary artery bypass graft surgery in Phase III clinical trials.

ExcerptReferenceRelevance
"Acadesine has proven intravenous efficacy in the amelioration of ischaemic reperfusion injury associated with coronary artery bypass graft surgery in Phase III clinical trials. "( Acadesine, an adenosine-regulating agent with the potential for widespread indications.
Drew, BG; Kingwell, BA, 2008
)
3.23
"Acadesine has shown in vitro to selectively induce apoptosis in B cells from chronic lymphocytic leukemia (CLL) patients. "( Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study.
Campàs, C; Cazin, B; de Frias, M; González-Barca, E; Janssens, A; Levy, V; Pérez de Oteyza, J; Saunders, A; Terol, MJ; Van Den Neste, E; Zachee, P, 2013
)
3.28
"Acadesine has been shown to selectively cause the death of B-cells, whilst sparing T-cells when administered to blood samples taken from patients with B-CLL."( Acadesine: AICA riboside, ARA 100, arasine, GP 1 110.
, 2008
)
2.51

Actions

Acadesine can inhibit the upregulation of leukocyte CD11b adhesion receptors. Treatment in patients before and during surgery can reduce early cardiac death, myocardial infarction, and combined adverse cardiovascular outcomes.

ExcerptReferenceRelevance
"Acadesine and adenosine inhibit up-regulation of granulocyte CD11b in vitro, and acadesine is capable of a similar inhibition during in vivo cardiopulmonary bypass."( Acadesine inhibits neutrophil CD11b up-regulation in vitro and during in vivo cardiopulmonary bypass.
Auszura, LA; Davis, E; Mathew, JP; O'Connor, T; Rinder, CS; Smith, BR; Tracey, JB, 1995
)
2.46
"Acadesine can inhibit the upregulation of leukocyte CD11b adhesion receptors, and treatment in patients before and during surgery can reduce early cardiac death, myocardial infarction, and combined adverse cardiovascular outcomes."( Cardiopulmonary bypass-induced inflammation: is it important?
Hill, GE, 1998
)
1.02

Treatment

Acadesine reduced mortality by 4.3-fold, from 27.8% (15 of 54; placebo) to 6.5% (3 of 46; acadesine) (p = 0.006) Treatment significantly attenuated the mucosal lesions seen during reperfusion.

ExcerptReferenceRelevance
"Acadesine treatment, however, reduced that mortality by 4.3-fold, from 27.8% (15 of 54; placebo) to 6.5% (3 of 46; acadesine) (p = 0.006), with the principal benefit occurring over the first 30 days after MI."( Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine.
Dietzel, C; Mangano, DT; Miao, Y; Tudor, IC, 2006
)
1.27
"Acadesine treatment significantly attenuated the mucosal lesions seen during reperfusion."( Effect of acadesine treatment on postischemic damage to small intestine.
Beger, HG; Gruber, H; Marzinzig, E; Marzinzig, M; Mattfeldt, T; Moch, D; Poch, B; Schoenberg, MH, 1995
)
1.41
"Acadesine treatment in patients at risk for embolic stroke could potentially lead to cerebral protection."( Acadesine reduces indium-labeled platelet deposition after photothrombosis of the common carotid artery in rats.
Alexis, N; Dewanjee, MK; Dewanjee, S; Dietrich, WD; Gruber, H; Miller, LP; Prado, R, 1995
)
2.46
"Pretreatment with acadesine dramatically suppressed the clotting activity and expression of TF (protein and mRNA)."( Acadesine inhibits tissue factor induction and thrombus formation by activating the phosphoinositide 3-kinase/Akt signaling pathway.
Belcher, JD; Geng, JG; Huo, Y; Slungaard, A; Tang, R; Viollet, B; Wang, H; Wang, J; Wu, C; Zhang, C; Zhang, W; Zhu, C, 2010
)
2.13
"(3) Treatment with acadesine (2.5 mg.kg-1.min-1 intravenously for 5 min starting 155 min prior to 30 min ischaemia followed by 210 min infusion of 0.5 mg.kg-1.min-1."( Acadesine extends the window of protection afforded by ischaemic preconditioning.
Burckhartt, B; Cohen, MV; Downey, JM; Mullane, KM; Tsuchida, A; Yang, XM, 1994
)
2.05
"Treatment with acadesine alone did not modify the infarct size [37.8(3.5)%], but both of the acadesine plus preconditioning groups showed a significant limitation of infarct size with 13.9(3.1)% infarction in group 4 and 12.7(2.2)% infarction in group 5 (both p < 0.01 v control)."( Acadesine extends the window of protection afforded by ischaemic preconditioning.
Burckhartt, B; Cohen, MV; Downey, JM; Mullane, KM; Tsuchida, A; Yang, XM, 1994
)
2.07

Toxicity

ExcerptReferenceRelevance
" The goals of this study were to evaluate safety and the effects of acadesine on myocardial ischemia, left ventricular function, and, secondarily, on adverse clinical outcomes (myocardial infarction, heart failure, life-threatening dysrhythmias, and death) in patients undergoing CABG surgery."( An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. SPI Research Group.
Barash, P; Curling, P; Hollenberg, M; Leung, JM; Mangano, DT; Mathew, J; Reves, JG; Salmenpera, M; Stanley, T, 1994
)
0.75

Compound-Compound Interactions

ExcerptReferenceRelevance
" In summary, our results suggest that acadesine exerts a cytotoxic effect in MCL in combination with rituximab, by decreasing the proliferative and survival signatures of the disease, thus supporting the clinical examination of this strategy in MCL patients."( Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma.
Beà, S; Campàs, C; Colomer, D; de Frias, M; Kalko, SG; López-Guerra, M; Montraveta, A; Pérez-Galán, P; Rosich, L; Roué, G; Salaverria, I; Xargay-Torrent, S, 2014
)
0.95

Bioavailability

Acadesine is an adenosine-regulating agent. It has important metabolic effects. It is partly through activation of the key metabolic regulatory enzyme, AMP-activated protein kinase.

ExcerptReferenceRelevance
" The drug was poorly bioavailable (less than 5%) when administered orally in solution."( AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent.
Dewland, P; Dixon, R; Fujitaki, J; Gourzis, J; Gruber, H; McDermott, D, 1991
)
0.28
"Acadesine is an adenosine-regulating agent that increases bioavailability of adenosine and has important metabolic effects, partly through activation of the key metabolic regulatory enzyme, AMP-activated protein kinase."( Acadesine, an adenosine-regulating agent with the potential for widespread indications.
Drew, BG; Kingwell, BA, 2008
)
3.23
" AMPK-activating agents with high oral bioavailability have potential application in impaired glucose tolerance, insulin resistance and types 1 and 2 diabetes, however the poor oral bioavailability of acadesine precludes such application."( Acadesine, an adenosine-regulating agent with the potential for widespread indications.
Drew, BG; Kingwell, BA, 2008
)
1.98
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The postischemic recoveries of aortic flow were 15. In dose-response studies, acadesine (0, 5, 20, 50, 200, and 1,000 mumol/l) was given only as a cardioplegic additive.

ExcerptRelevanceReference
" In dose-response studies, acadesine (0, 5, 20, 50, 200, and 1,000 mumol/l; n = 12 per group) was given only as a cardioplegic additive; the postischemic recoveries of aortic flow were 15."( Acadesine and myocardial protection. Studies of time of administration and dose-response relations in the rat.
Bullough, D; Galiñanes, M; Hearse, DJ; Mullane, KM, 1992
)
2.02
" We determined the adenine nucleotide de novo synthesis in the dog by infusion of [14C]glycine and the acceleration of adenine nucleotide built up by intracoronary infusion of ribose together with [14C]glycine or radiolabeled 5-amino-4-imidazolcarboxamide riboside or adenosine in the same animal model and with the same dosage of substrates (9 mmol) in postischemic and nonischemic myocardial tissue."( Influence of ribose, adenosine, and "AICAR" on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog.
Hoffmeister, HM; Mauser, M; Nienaber, C; Schaper, W, 1985
)
0.27
" One hundred sixteen patients were randomized to receive one of three continuous intravenous dosing regimens (placebo [control] or one of two doses of acadesine [high- and low-dose infusion]) in double-blind fashion intraoperatively and in the early postoperative period (total infusion time was 7 h)."( An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. SPI Research Group.
Barash, P; Curling, P; Hollenberg, M; Leung, JM; Mangano, DT; Mathew, J; Reves, JG; Salmenpera, M; Stanley, T, 1994
)
0.71
" AICA and adenosine excretions increased during the day of MTX dosing (treatment day) compared to the previous baseline day in animals responding well to MTX (i."( Methotrexate and erythro-9-(2-hydroxynon-3-yl) adenine therapy for rat adjuvant arthritis and the effect of methotrexate on in vivo purine metabolism.
Baggott, JE; Morgan, SL, 2007
)
0.34
" Chemotherapy has a narrow therapeutic window and requires high dosage treatment in patients with advanced-stage cancers and further need innovative treatment strategies."( Breast cancer: insights in disease and influence of drug methotrexate.
Amorim, I; Gärtner, F; Gouveia, MJ; Koksch, B; Santos, J; Vale, N; Yang, V, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
1-ribosylimidazolecarboxamide
aminoimidazoleAny member of the class of imidazoles carrying at least one amino substituent.
nucleoside analogueAn analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Purine metabolism1336
4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression011
Purine metabolism and related disorders2353

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency70.79460.004023.8416100.0000AID485290
farnesoid X nuclear receptorHomo sapiens (human)Potency1.67840.375827.485161.6524AID743220
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency26.60320.001723.839378.1014AID743083
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (130)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1853007Cytotoxicity against paclitaxel-resistant human HCT116tax cells assessed as reduction on cell viability at 100 to 200 uM incubated for 48 hrs in presence of paclitaxel by MTT assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1742263Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in serum AST level at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1495072Cytotoxicity in drug sensitive human K562 cells assessed as reduction cell viability incubated for 48 hrs by XTT assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Modular synthesis of new C-aryl-nucleosides and their anti-CML activity.
AID1742323In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in mTOR phosphorylation in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1742248Activation of AMPK in oleic, palmitic, linoleic and arachidonic acid 29:47:18:6 (v/v)-induced human HepG2 cells assessed as increase in AMPK phosphorylation by Western blot2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1481742Induction of autophagy in human RCC4 cells assessed as increase in LC3 conversion at 1 mM after 48 hrs by Western blot method2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Synthesis and anti-cancer activities of new sulfonamides 4-substituted-triazolyl nucleosides.
AID1237588Inhibition of adipogenesis in mouse 3T3L1 cells assessed as reduction in triglyceride content at 0.2 mM by colorimetric assay2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogenesis/lipogenesis in 3T3-L1 adipocytes.
AID1481734Anticancer activity against human MDA-MB-231 cells after 48 hrs by XTT assay2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Synthesis and anti-cancer activities of new sulfonamides 4-substituted-triazolyl nucleosides.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1055505Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID1853001Cytotoxicity against human HCT-116 cells overexpressing human BCRP incubated for 48 hrs by MTT assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1237602Reduction in FAS protein expression in mouse 3T3L1 cells at 0.2 mM after 3 days by Western blot method2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogenesis/lipogenesis in 3T3-L1 adipocytes.
AID1852996Cytotoxicity against in human HCT-116 cells overexpressing human BCRP assessed as DNA damage by measuring fluorescence intensity at 100 uM incubated for 30 mins by Hoechst 33342 staining accumulation assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1742283Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as spleen index at 100 mg/kg, po measured after 24 hrs (Rvb = 3.87 +/- 0.05 No_unit)2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1852994Cytotoxicity against paclitaxel-resistant human HCT116tax cells assessed as DNA damage by measuring fluorescence intensity incubated for 30 mins by Hoechst 33342 staining accumulation assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1168140Inhibition of triglyceride accumulation in mouse 3T3L1 cells at 10 uM after 24 hrs2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and lipid-lowering evaluation of 3-methyl-1H-purine-2,6-dione derivatives as potent and orally available anti-obesity agents.
AID1154418Activation of AMPK in C57BL/6J mouse skeletal muscle assessed as increase of PGC-1alpha transcription at 500 mg/kg, sc after 2 hrs by Western blot analysis2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Petasin activates AMP-activated protein kinase and modulates glucose metabolism.
AID1237591Increase in AMPKalpha Thr172 phosphorylation in mouse 3T3L1 cells at 0.2 mM after 9 days by Western blot method2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogenesis/lipogenesis in 3T3-L1 adipocytes.
AID1742282Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as kidney index at 100 mg/kg, po measured after 24 hrs (Rvb = 11.20 +/- 0.58 No_unit)2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1481733Anticancer activity against human RCC4 cells after 48 hrs by XTT assay2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Synthesis and anti-cancer activities of new sulfonamides 4-substituted-triazolyl nucleosides.
AID1742313In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in AMPKalpha phosphorylation in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1853006Cytotoxicity against human wild type HCT-116 cells assessed as reduction on cell viability at 100 to 200 uM incubated for 48 hrs in presence of paclitaxel by MTT assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1742319In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in SREBP1-C expression in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1853002Cytotoxicity against human HEK293 cells incubated for 48 hrs by MTT assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1742314In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in AMPKalpha phosphorylation in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1853010Cytotoxicity against human HCT-116 cells overexpressing human ABCG2 assessed as reduction on ABCG2 gene expression level by RT-qPCR method2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1853008Inhibition of recombinant human P-gp ATPase activity in presence of MgATP preincubated for 40 min measured after 20 min by Pgp-Glo assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1742326In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in PPARalpha expression in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1055515Cytostatic activity against thymidine kinase-deficient human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID1742285Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as epididymis white adipose tissue index at 100 mg/kg, po measured after 24 hrs (Rvb = 23.43 +/- 3.10 No_unit)2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1666799Aqueous solubility of the compound in pH 6.8 JP2 fluid incubated for 20 hrs by liquid chromatography2020Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5
Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer.
AID1726951Activation of AMPK pathway in mouse 3T3-L1 cells assessed as increase in number of mitochondria copy at 2 uM after 24 hrs in presence of compound C by mito-tracker staining based Confocal microscopic method2020European journal of medicinal chemistry, Apr-15, Volume: 192Discovery of a promising agent IQZ23 for the treatment of obesity and related metabolic disorders.
AID1678851Antitumor activity against human MCF7 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 200 mg/kg, ip administered every other day for 2 weeks relative to control2020RSC medicinal chemistry, Jun-01, Volume: 11, Issue:6
Breast cancer: insights in disease and influence of drug methotrexate.
AID1464905Inhibition of PTP1B in differentiated mouse C2C12 cells assessed as upregulation of ACC phosphorylation at Ser-79 residue at 0.2 mM after 30 mins by Western blot assay2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
PTP1B inhibitors from the seeds of Iris sanguinea and their insulin mimetic activities via AMPK and ACC phosphorylation.
AID1825235Effect on AMPK in mouse C2C12 myotubes assessed as increase in AMPK-alpha phosphorylation at Thr172 at 1 mM measured after 1 hrs by western blot analysis
AID1055502Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathicity2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID1742271Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in lipid level in liver at 100 mg/kg, po measured after 24 hrs by Oil Red O staining based assay2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1237592Activation of AMPK in mouse 3T3L1 cells assessed as increase in ACC Ser79 phosphorylation at 0.2 mM after 9 days by Western blot method2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogenesis/lipogenesis in 3T3-L1 adipocytes.
AID1742317In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in CPT-1A phosphorylation in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1742318In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in CPT-1A phosphorylation in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1166576Activation of AMPK in mouse 3T3L1 cells assessed as AMPK phosphorylation at 500 uM after 5 hrs by Western blotting analysis2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
2-(2-Bromophenyl)-formononetin and 2-heptyl-formononetin are PPARγ partial agonists and reduce lipid accumulation in 3T3-L1 adipocytes.
AID1237601Reduction in C/EBPalpha protein expression in mouse 3T3L1 cells at 0.2 mM after 3 days by Western blot method2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogenesis/lipogenesis in 3T3-L1 adipocytes.
AID1853003Cytotoxicity against human HCT-116 cells assessed as reduction on cell viability at 100 uM incubated for 48 hrs in presence of paclitaxel by MTT assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1055518Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID1742262Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in serum LDL level at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1742312In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in AKT phosphorylation in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1853000Cytotoxicity against human HCT-116 cells overexpressing human MDR1 incubated for 48 hrs by MTT assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1666795Antiproliferation activity against human MDA-MB-453 cells assessed as reduction in cell viability measured after 4 days by Celltiter-glo luminescent cell viability assay2020Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5
Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer.
AID1742281Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as liver index at 100 mg/kg, po measured after 24 hrs (Rvb = 65.00 +/- 0.87 No_unit)2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1742328In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in PPARbeta expression in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1726950Activation of AMPK pathway in mouse 3T3-L1 cells assessed as increase in number of mitochondria copy at 2 uM after 24 hrs by mito-tracker staining based Confocal microscopic method2020European journal of medicinal chemistry, Apr-15, Volume: 192Discovery of a promising agent IQZ23 for the treatment of obesity and related metabolic disorders.
AID1742264Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in serum ALT level at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1055520Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID1852999Cytotoxicity against paclitaxel-resistant human HCT116tax cells incubated for 48 hrs by MTT assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1742325In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in PPARalpha expression in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1853009Cytotoxicity against human HCT-116 cells overexpressing human ABCB1 assessed as reduction on ABCB1 gene expression level by RT-qPCR method2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1495073Cytotoxicity in imatinib-resistant human K562R cells assessed as reduction cell viability incubated for 48 hrs by XTT assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Modular synthesis of new C-aryl-nucleosides and their anti-CML activity.
AID1055516Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID1852998Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1742267Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in serum IL6 level at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1353575Induction of AMPKalpha phosphorylation at Thr172 residue in mouse 3T3L1 cells at 2 mM after 4 hrs by Western blot analysis2018European journal of medicinal chemistry, Mar-10, Volume: 147Design, synthesis and biological evaluation of novel bouchardatine analogs as potential inhibitors of adipogenesis/lipogenesis in 3T3-L1 adipocytes.
AID1742321In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in FAS expression in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1237584Effect on in AMPKalpha protein expression in mouse 3T3L1 cells at 25 uM after 0.5 to 4 hrs by Western blot method2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogenesis/lipogenesis in 3T3-L1 adipocytes.
AID1055501Cytotoxicity against HEL cells2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID1742249Activation of AMPK in oleic, palmitic, linoleic and arachidonic acid 29:47:18:6 (v/v)-induced human HepG2 cells assessed as increase in ACC phosphorylation by Western blot2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1742260Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in serum total cholesterol level at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1237598Reduction in SCD1 protein expression in mouse 3T3L1 cells at 0.2 mM after 3 days by Western blot method2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogenesis/lipogenesis in 3T3-L1 adipocytes.
AID1666797Antiproliferation activity against human SK-BR-3 cells assessed as reduction in cell viability measured after 4 days by Celltiter-glo luminescent cell viability assay2020Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5
Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer.
AID1055503Antiviral activity against acyclovir-resistant thymidine kinase-deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID1666800Aqueous solubility of the compound in pH 6.8 JP2 fluid incubated for 20 hrs in presence of taurocholic acid by liquid chromatography2020Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5
Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer.
AID1742322In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in FAS expression in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1742329In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in PPARgamma expression in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1742269Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in fatty liver phenotype at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1332115Activation of AMPK in mouse C2C12 cells assessed as increase in ACC phosphorylation at Ser79 residues at 1 mM after 1 hr by Western blot analysis2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Anthraquinones from Morinda longissima and their insulin mimetic activities via AMP-activated protein kinase (AMPK) activation.
AID1742284Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as perirenal white adipose tissue index at 100 mg/kg, po measured after 24 hrs (Rvb = 18.14 +/- 1.44 No_unit)2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1742327In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in PPARbeta expression in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1742273Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in appearance of hepatic lobules at 100 mg/kg, po measured after 24 hrs by Oil Red O staining based assay2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1237599Reduction in SREBP-1c protein expression in mouse 3T3L1 cells at 0.2 mM after 3 days by Western blot method2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogenesis/lipogenesis in 3T3-L1 adipocytes.
AID1742261Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in serum triglyceride level at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1666798Aqueous solubility of the compound in pH 1.2 JP1 fluid incubated for 20 hrs by liquid chromatography2020Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5
Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer.
AID1742320In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in SREBP1-C expression in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1666796Activation of AMPK in human MDA-MB-435 cells measured after 2 hrs by anti-phospho-Acetyl-CoA Carboxylase (Ser79) antibody-based ELISA2020Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5
Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer.
AID1742316In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in ACC phosphorylation in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1237600Reduction in PPARgamma protein expression in mouse 3T3L1 cells at 0.2 mM after 3 days by Western blot method2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogenesis/lipogenesis in 3T3-L1 adipocytes.
AID1742324In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in mTOR phosphorylation in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1742330In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in PPARgamma expression in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1742311In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in AKT phosphorylation in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1853005Cytotoxicity against human HCT-116 cells assessed as reduction on cell viability at 100 uM incubated for 48 hrs by MTT assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1437968Antileukemic activity against human K562 cells after 48 hrs by XTT assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies.
AID1742315In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in ACC phosphorylation in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1612306Activation of GSK3 phosphorylation in human HepG2 cells at MNTD after 18 hrs by Western blot analysis relative to control2018Journal of natural products, 10-26, Volume: 81, Issue:10
Bioactive Pentacyclic Triterpenes from the Root Bark Extract of Myrianthus arboreus, a Species Used Traditionally to Treat Type-2 Diabetes.
AID1055504Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID1852995Cytotoxicity against human HCT-116 cells overexpressing human MDR1 assessed as DNA damage by measuring fluorescence intensity at 100 uM incubated for 30 mins by Hoechst 33342 staining accumulation assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (272)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (8.46)18.7374
1990's79 (29.04)18.2507
2000's73 (26.84)29.6817
2010's79 (29.04)24.3611
2020's18 (6.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.87 (24.57)
Research Supply Index5.68 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index37.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (5.05%)5.53%
Reviews18 (6.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other245 (88.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]